Crestor and Tadalafil Interaction: Safety, Mechanisms, and Clinical Guidance
Rosuvastatin (brand name Crestor) is an HMG-CoA reductase inhibitor ("statin") used to lower LDL cholesterol and reduce cardiovascular risk. Tadalafil (brand name Cialis, also sold generically) is a PDE5 inhibitor approved for erectile dysfunction and for benign prostatic hyperplasia (BPH) symptoms, typically taken either on demand or as a low daily dose. Patients who need both, which is common in men with cardiovascular risk factors who also have ED or BPH, reasonably ask whether the two prescriptions conflict.
The direct answer: rosuvastatin and tadalafil do not share a metabolic pathway that would predict a clinically meaningful pharmacokinetic interaction. Rosuvastatin undergoes only limited hepatic metabolism (mainly via CYP2C9) and depends on hepatic uptake transporters (OATP1B1, BCRP) for clearance, while tadalafil is cleared predominantly through CYP3A4. Neither drug is a meaningful inhibitor or inducer of the other's clearance pathway. This is different from statins that are extensively CYP3A4-metabolized (notably simvastatin, and to a lesser degree atorvastatin), where a PDE5 inhibitor pairing carries more theoretical overlap. The current FDA labels for rosuvastatin and tadalafil do not list the other drug as a contraindication or as a substance requiring dose adjustment. That absence of a labeled interaction is the strongest available evidence anchor for this specific pairing; it is not the same as a dedicated interaction study proving safety in all patients.
Why this pairing gets asked about
Statins as a drug class include some well-known interactions, largely tied to CYP3A4-metabolized members of the class (simvastatin, and atorvastatin to a lesser extent) combined with strong CYP3A4 inhibitors such as certain macrolides, azole antifungals, and HIV protease inhibitors. Rosuvastatin sits apart from that pattern because so little of the dose depends on CYP metabolism. Patients and even some clinicians extrapolate statin-class caution to rosuvastatin without accounting for that pharmacokinetic difference, which is the confusion this page is trying to resolve.
What each drug's clearance pathway actually looks like
According to the current FDA prescribing information for rosuvastatin, roughly 10% of an oral dose is metabolized hepatically, primarily via CYP2C9, with the majority of the drug cleared unchanged through biliary and renal routes. Hepatic uptake depends on the transporters OATP1B1 and BCRP rather than CYP-driven first-pass metabolism. This transporter dependence is why rosuvastatin interacts with drugs that inhibit those transporters, such as cyclosporine and certain HIV protease inhibitors, and why the label carries specific renal-impairment and Asian-ancestry dosing caps.
According to tadalafil's FDA prescribing information, the drug is cleared predominantly through CYP3A4-mediated hepatic metabolism, and its exposure rises substantially with strong CYP3A4 inhibitors (the label specifies dose-reduction requirements in that setting) and falls with strong CYP3A4 inducers. The label's own drug-interaction table does not list rosuvastatin, or statins generally, among the substances that meaningfully change tadalafil exposure.
Because rosuvastatin is not a CYP3A4 substrate, inhibitor, or inducer of clinical consequence, and tadalafil does not meaningfully affect OATP1B1 or BCRP transport, the two drugs are not predicted to change each other's blood levels. This is a mechanistic inference from each drug's own labeled clearance pathway rather than a finding from a dedicated rosuvastatin-tadalafil interaction trial; a dedicated crossover pharmacokinetic study in this specific pairing does not appear to be publicly available, and that gap should be stated plainly rather than papered over.
The pharmacodynamic overlap: blood pressure
Tadalafil produces mild vasodilation through the nitric oxide/cGMP pathway and is associated with a small average reduction in blood pressure, an effect that is well documented in its FDA label and clinical trial program. Statins as a class have been studied for blood-pressure effects, and some meta-analyses report a small additional systolic reduction, though results across studies are inconsistent and the effect size in the literature is not settled enough to state a precise number here without checking the primary paper. Practically, an additive blood-pressure effect from combining tadalafil with any antihypertensive-adjacent therapy is plausible but modest, and is only likely to matter clinically in patients who are already hypotensive, on multiple vasodilating agents, or on alpha-blockers, where the tadalafil label itself already calls for caution independent of statin use.
The interaction that actually carries a hard contraindication is tadalafil with organic nitrates. Tadalafil's label describes a clinically dangerous, potentially severe hypotensive interaction with nitrates in any form, regular or intermittent, and lists this as a contraindication. That warning is frequently and incorrectly generalized to "tadalafil plus any cardiovascular drug," including statins. Statins do not release nitric oxide or affect cGMP signaling at therapeutic doses, so the nitrate mechanism does not apply to rosuvastatin.
Myalgia: two possible causes, one overlapping symptom
Both drugs list myalgia or musculoskeletal pain as a listed adverse effect, which can create diagnostic confusion if a patient reports new muscle pain after starting the combination.
Statin-associated muscle symptoms are a recognized clinical entity, ranging from mild myalgia to, rarely, rhabdomyolysis. Guideline bodies (the 2018 multisociety cholesterol guideline and related statin-safety statements) recommend checking creatine kinase (CK) when a patient on a statin reports new or worsening muscle symptoms, and recommend stopping the statin pending evaluation if CK rises to many multiples of the upper limit of normal, or if symptoms are severe. Precise incidence figures for rosuvastatin-specific myopathy and rhabdomyolysis vary by data source and should be verified against the current label or a recent systematic review rather than quoted from memory.
Tadalafil-associated back pain and myalgia are a separately described, dose-related adverse effect in the tadalafil label, generally self-limited. A pattern where muscle or back discomfort appears in temporal relation to tadalafil dosing and resolves within a day or two is more consistent with the PDE5-inhibitor pattern than with statin myopathy, which tends to be more persistent and progressive. This is a clinically useful distinguishing pattern, but it is a practical heuristic, not a validated diagnostic rule, and any new, persistent, or severe muscle symptom in a patient on a statin still warrants CK testing and clinical evaluation rather than being assumed to be tadalafil-related.
Hepatic monitoring
Statin labeling and the 2018 cholesterol guideline support checking baseline liver enzymes (ALT/AST) before starting a statin, with repeat testing driven by symptoms rather than routine intervals. Tadalafil is hepatically cleared but is not associated with a distinct hepatotoxicity signal in its label, and does not require routine liver monitoring. There is no established evidence that combining the two drugs produces additive hepatic risk beyond what either drug carries alone; this is an area where the absence of a signal is the relevant finding, not proof of long-term safety in every patient population.
Dose adjustment: usually not needed, with named exceptions
Neither label requires a dose change specifically because the other drug is present. Exceptions that matter independent of this particular pairing:
- Rosuvastatin dosing is capped and requires a lower starting dose in patients with significant renal impairment, and exposure is higher in patients of Asian ancestry, per the FDA label.
- Tadalafil dosing must be reduced when a strong CYP3A4 inhibitor is present (examples given in the label include certain azole antifungals and some protease inhibitors) and is contraindicated, or requires specific caution, with nitrates and in some cases with alpha-blockers, independent of any statin.
- Patients on drugs that inhibit OATP1B1 or BCRP (cyclosporine, some HIV protease inhibitors, gemfibrozil) need rosuvastatin dose caution regardless of tadalafil use.
A patient who is on rosuvastatin, tadalafil, and a drug from either exception list at the same time has a more complex interaction picture than the simple two-drug question this page addresses, and that scenario should be reviewed individually by a pharmacist or prescriber rather than generalized from this guidance.
Evidence-status interaction assessment
| Claim | Status | Basis | What still needs verification |
|---|---|---|---|
| Rosuvastatin is not a CYP3A4 substrate/inhibitor/inducer | Established | Current FDA rosuvastatin label | None; stable label fact, re-check label date before relying on it clinically |
| Tadalafil is cleared predominantly via CYP3A4 | Established | Current FDA tadalafil label | None; stable label fact |
| No dedicated rosuvastatin + tadalafil pharmacokinetic interaction trial | Not established (absence of data) | No public interaction study located for this specific pair | Confirm no unpublished or newer study exists before stating "no interaction" as a proven fact rather than an inference |
| No clinically meaningful PK interaction is predicted between the two drugs | Plausible, mechanistically supported | Non-overlapping clearance pathways per both labels | This is an inference from mechanism, not a measured outcome; treat as reasonable but not definitively "tested" |
| Tadalafil produces a small average BP reduction; statins may add a small additional reduction | Established for tadalafil alone; plausible but inconsistent for statins | Tadalafil FDA label; statin BP literature is mixed | Specific numeric effect sizes for statins on BP should be checked in a current systematic review, not quoted from memory |
| Statin myopathy and tadalafil-related myalgia are mechanistically distinct | Established as separate, independently described adverse effects | Rosuvastatin and tadalafil FDA labels; general statin-safety guidance on CK monitoring | Distinguishing them at the bedside is a clinical heuristic, not a validated diagnostic algorithm |
| Nitrate contraindication applies to tadalafil, not to statins | Established | Tadalafil FDA label | None; but this point is worth restating to patients who conflate it with statin caution |
| Combined hepatotoxicity risk from co-administration | Not established | No signal identified in either label for this combination | Absence of evidence is not proof of long-term safety; monitor per standard statin practice |
Before assuming the combination is routine, a clinician or pharmacist should verify: the patient's full medication list for CYP3A4 inhibitors/inducers or OATP1B1/BCRP inhibitors that could independently affect either drug; any nitrate use, current or as-needed, which is a hard stop for tadalafil regardless of statin status; baseline blood pressure and hemodynamic stability if the patient is also on an alpha-blocker or multiple antihypertensives; and baseline liver enzymes per standard statin-initiation practice, not because of the tadalafil addition itself.
Evidence boundary
What is established: rosuvastatin and tadalafil rely on distinct, non-overlapping clearance mechanisms, and neither current FDA label lists the other as a contraindicated or dose-adjusting interaction. What is plausible but unproven: that this mechanistic independence guarantees no interaction in every patient, including those with hepatic or renal impairment, polypharmacy, or genetic variation in transporter or CYP activity, since no dedicated interaction trial for this specific pair was located. What is not established: precise incidence figures for combined adverse effects (myalgia overlap, additive blood pressure change) in patients taking both drugs together, as opposed to each drug's individually studied adverse-effect rate. Readers and clinicians should treat this as a low-concern pairing based on mechanism and labeling, not as a pairing that has been directly tested and proven safe in a dedicated trial.
When urgent evaluation is appropriate
Severe or rapidly worsening muscle pain, dark urine, or profound weakness after starting or continuing either drug warrants prompt medical evaluation for possible rhabdomyolysis, regardless of which drug is presumed responsible. Chest pain, prolonged erection (priapism), sudden vision or hearing changes, or symptomatic hypotension after tadalafil dosing, especially in a patient who may have taken a nitrate, requires emergency care.
Frequently asked questions
Can I take Crestor with tadalafil?
Does rosuvastatin interact with PDE5 inhibitors like tadalafil through the same pathway as other statins?
What is the real contraindication with tadalafil that people confuse with statins?
Can tadalafil cause muscle pain similar to statins?
Do I need extra monitoring if I take both drugs?
References
- AstraZeneca. Crestor (rosuvastatin calcium) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021366s045lbl.pdf
This article is intended for general education and does not replace individualized medical or pharmacist advice. It is pending qualified clinical review before publication.